Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy

Journal of Clinical Lipidology

Volumn 9, Issue 6, 2015, Pages 832-836

  Basani, Samata ^a,b   Garg, Abhimanyu ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

Author keywords

Bexarotene; Dyslipidemia; Low HDL; Retinoids

Indexed keywords

AMLODIPINE; ATORVASTATIN; BEXAROTENE; CHOLESTEROL ESTER TRANSFER PROTEIN; DOXEPIN; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LEVOTHYROXINE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METHOXSALEN; ROSUVASTATIN; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL; TRIAMCINOLONE; UREA; HIGH DENSITY LIPOPROTEIN; TETRALIN DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FREE THYROXINE INDEX; HUMAN; HYPOCHOLESTEROLEMIA; HYPOTHYROIDISM; LOW DRUG DOSE; LYMPHOCYTE TRANSFUSION; MIDDLE AGED; NONHODGKIN LYMPHOMA; PHOTOTHERAPY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DOSE RESPONSE; LYMPHOMA, NON-HODGKIN;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIPOPROTEINS, HDL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; TETRAHYDRONAPHTHALENES;

EID: 84949640070     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.08.004     Document Type: Article

References (20)

1. S.I. Sherman, J. Gopal, B.R. Haugen, and et al. Central hypothyroidism associated with retinoid X receptor-selective ligands N Engl J Med 340 1999 1075 1079
2. J. de Vries-van der Weij, W. de Haan, L. Hu, and et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein Endocrinology 150 2009 2368 2375
3. M. Duvic, A.G. Martin, Y. Kim, et al. Worldwide Bexarotene Study G Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch Dermatol 137 2001 581 593
4. R. Ramlau, P. Zatloukal, J. Jassem, and et al. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I J Clin Oncol 26 2008 1886 1892
5. F. Lalloyer, C. Fievet, S. Lestavel, and et al. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia Arterioscler Thromb Vasc Biol 26 2006 2731 2737
6. N. Vu-Dac, P. Gervois, I.P. Torra, and et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids J Clin Invest 102 1998 625 632
7. E. Florentin, A. Athias, and L. Lagrost Modulation of the activity of the human cholesteryl ester transfer protein by carboxylated derivatives. Evidence for 13-cis-retinoic acid as a potent activator of the protein's activity in plasma Eur J Biochem 240 1996 699 706
8. M. Dedecjus, D. Masson, T. Gautier, and et al. Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short-term hypothyroidism. Lack of relationship to lipoprotein abnormalities Clin Endocrinol 58 2003 581 588
9. W.P. Castelli, R.J. Garrison, P.W. Wilson, R.D. Abbott, S. Kalousdian, and W.B. Kannel Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study JAMA 256 1986 2835 2838
10. J.P. Despres, I. Lemieux, G.R. Dagenais, B. Cantin, and B. Lamarche HDL-cholesterol as a marker of coronary heart disease risk: the Quebec Cardiovascular Study Atherosclerosis 153 2000 263 272
11. Investigators A-H W.E. Boden, J.L. Probstfield, T. Anderson, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
12. P.J. Barter, M. Caulfield, M. Eriksson, et al. Investigators I Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
13. G.G. Schwartz, A.G. Olsson, M. Abt, et al. dal OI Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
14. Group HTC M.J. Landray, R. Haynes, J.C. Hopewell, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
15. C. Serfaty-Lacrosniere, F. Civeira, A. Lanzberg, and et al. Homozygous Tangier disease and cardiovascular disease Atherosclerosis 107 1994 85 98
16. C.L. Haase, A. Tybjaerg-Hansen, A.A. Qayyum, J. Schou, B.G. Nordestgaard, and R. Frikke-Schmidt LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals J Clin Endocrinol Metab 97 2012 E248 E256
17. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, and et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
18. L. Pisciotta, R. Miccoli, A. Cantafora, and et al. Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency Atherosclerosis 167 2003 335 345
19. R. Talpur, S. Ward, N. Apisarnthanarax, J. Breuer-Mcham, and M. Duvic Optimizing bexarotene therapy for cutaneous T-cell lymphoma J Am Acad Dermatol 47 2002 672 684
20. J.J. Scarisbrick, S. Morris, R. Azurdia, and et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma Br J Dermatol 168 2013 192 200